At Sinotau, our dedication is unwavering in advancing the development, production, and introduction of radiopharmaceuticals that adhere to the highest industry standards in terms of quality, effectiveness, and innovation. Our product portfolio boasts practical applications in the realms of oncology, neurology, and cardiology, underscoring our commitment to pioneering solutions for better healthcare outcomes.
The first radiopharmaceutical targeting β-amyloid approved in China to be used to support early diagnosis of Alzheimer’s disease (AD)
Classic stress-inducing agents used for assisting in the diagnosis of myocardial ischemia
